Bristol-Myers Squibb has announced that ERBITUX in combination with FOLFIRI have been approved as a treatment for metastatic colorectal cancer (mCRC).
The clinical research specialist's solution was approved by the US Food and Drug Administration (FDA) after a number of tests, which also led to the QIAGEN's therascreen KRAS diagnostic kit being accepted for use.
Brian Daniels, senior vice president, global development and medical affairs, Bristol-Myers Squibb, said: "Today’s approval demonstrates our ability to bring diverse cancer therapies to market that address the needs of patients with KRAS mutation-negative (wild-type) mCRC."
Mr Daniels went on to say that cancer is a heterogeneous disease and that patients with mCRC should not be perceived as the same.
Recently, Bristol-Myers Squibb announced a new partnership with Emory University, which will enable more work to be completed in the field of investigational compounds.
It will see the two groups work together, with the university carrying out Phase II, Phase III and pediatric trials in the metropolitan Atlanta area in a bid to boost the development of Bristol-Myers Squibb's medicines